Rheumatology Calculators

All Rheumatology calculators

• DAS28 Rheumatoid Arthritis Disease Activity Calculator: Calculate DAS28 Rheumatoid Arthritis Disease Activity.Use calculator →
• SLEDAI Score Calculator: Lupus Disease Activity.Use calculator →

Medically reviewed by Dr. Taimoor Asghar, physician.

In short: Rheumatology calculators: DAS28 for rheumatoid arthritis activity and SLEDAI for lupus activity, with interpretation and limits. Browse the calculators below, each with an interpretation guide.

Rheumatology is the speciality of joints, connective tissue and systemic autoimmune disease, where the central clinical skill is judging how active a disease is right now. Rheumatoid arthritis and systemic lupus erythematosus (lupus) can smoulder quietly or flare destructively, and treatment decisions depend on measuring that activity rather than guessing at it. The two calculators in this library are the standardised instruments rheumatologists use for exactly this purpose: the DAS28 score for rheumatoid arthritis and the SLEDAI score for lupus. They are used by rheumatology teams, by GPs documenting referrals, and by students learning how disease activity is quantified in modern practice.

What rheumatology covers and which questions these tools answer

Rheumatology covers the inflammatory arthritides, of which rheumatoid arthritis is the commonest, the connective tissue diseases led by lupus, the vasculitides, crystal arthropathies such as gout, and the spondyloarthropathies. These are diseases of immune dysregulation rather than wear and tear, and their course is measured in flares and remissions rather than steady decline. The question the rheumatologist asks at every visit is therefore a dynamic one: is the disease active, is the current treatment working, and does therapy need to be escalated, held steady or tapered?

The DAS28 answers that question for rheumatoid arthritis. It combines four elements: the count of tender joints out of 28 specified joints, the count of swollen joints from the same set, an acute phase reactant (erythrocyte sedimentation rate or C-reactive protein), and the patient's global assessment of disease activity. The 28-joint count deliberately excludes the feet and ankles, a compromise made for practicality in clinic, and the resulting score places the patient on a continuous scale from remission through low, moderate and high disease activity.

The SLEDAI answers the equivalent question for lupus, a far more heterogeneous disease. Lupus can attack skin, joints, kidneys, blood cells, the serous membranes and the nervous system, so its activity instrument must range across all of them. SLEDAI scores 24 clinical and laboratory descriptors, each weighted according to its clinical importance, from seizures and psychosis down to rash, alopecia and low complement levels. The total rises with active, reversible inflammation and is designed to change between visits, making it both a clinical guide and the standard outcome measure in lupus trials.

When clinicians and students reach for these calculators

In the rheumatology clinic, DAS28 is the working language of treat-to-target care. Modern rheumatoid arthritis management sets an explicit target, usually remission or low disease activity, and adjusts disease-modifying drugs until that target is reached. The DAS28 is calculated at each visit, and the number drives the decision: escalate methotrexate, add a biologic, or hold steady. Trainees learn the score early because clinic letters, multidisciplinary discussions and biologic prescribing criteria are all written in its terms, and many health systems require a documented DAS28 above a threshold before funding advanced therapies.

SLEDAI is used wherever lupus is managed longitudinally: specialist lupus clinics, nephrology clinics following lupus nephritis, and clinical trials. Because lupus manifestations come and go, a standardised score prevents the common error of treating last month's flare or missing a smouldering one. A rising SLEDAI prompts a search for the newly active organ system and a review of immunosuppression, while a falling score after a treatment change is the objective evidence that the change worked.

Outside specialist clinics, both tools have supporting roles. A GP referring a patient with suspected inflammatory arthritis can document tender and swollen joint counts in DAS28 format, which tells the rheumatologist exactly what was found. Students on rheumatology attachments use the calculators to practise the joint examination systematically, because the 28-joint count is effectively a checklist of where to look and what to record. Researchers and auditors use both scores to compare disease activity across clinics and over time.

Reading the results: what the scores change in practice

In rheumatoid arthritis, the DAS28 band determines the next therapeutic move. Remission, conventionally a DAS28 below 2.6, is the signal to consider tapering therapy once it has been sustained; low disease activity is the acceptable alternative target in longstanding disease. Moderate and high activity, conventionally above 3.2 and 5.1 respectively, trigger escalation: optimising conventional disease-modifying drugs, switching agents, or starting a biologic or targeted synthetic drug where funding criteria are met. The score also sets the tempo of follow-up, with active disease reviewed more often.

In lupus, the SLEDAI total guides the intensity of immunosuppression and the urgency of organ assessment. New high-weighted items such as seizures, psychosis, visual disturbance or urinary casts point to major organ involvement and usually prompt urgent investigation and aggressive treatment, often with high-dose corticosteroids and agents such as cyclophosphamide or mycophenolate. Persistent low-grade activity from rash, arthritis or serology alone is managed very differently, often with antimalarials and modest adjustments. The change in score between visits matters as much as the absolute number: a SLEDAI that has fallen by several points after a treatment change is meaningful improvement, while a rising score despite treatment is treatment failure.

Both scores also change conversations. A patient told that their DAS28 has moved from high to low disease activity has a concrete measure of progress that supports adherence through months of immunosuppression. A lupus patient can see that a flare has objectively settled, which makes the discussion about tapering steroids, with all their side effects, a shared decision grounded in measurement rather than impression.

Limitations and pitfalls to respect

The DAS28 has well-known blind spots. Because the 28-joint count excludes the feet and ankles, a patient with active foot disease can score misleadingly low, and experienced rheumatologists examine the feet regardless of what the score says. The patient global assessment and tender joint count are influenced by pain from any cause, so coexisting fibromyalgia, osteoarthritis or depression can inflate the score and push a patient toward escalation they do not need. The erythrocyte sedimentation rate rises with age and anaemia and falls for reasons unrelated to joints, which is why the CRP-based version is often preferred and why neither version should be read without the clinical picture.

SLEDAI measures activity, not damage and not the whole patient. A patient with burnt-out disease but extensive organ damage from years of lupus can have a low SLEDAI alongside major disability, and the score will not capture fatigue, pain or the burden of treatment, which often dominate the patient's experience. Serological items such as anti-dsDNA and complement can lag behind clinical change, and some manifestations that matter to patients, including certain forms of skin disease, are weighted lightly or absent. SLEDAI is also validated for lupus; applying it to other connective tissue diseases is inappropriate.

Both instruments are snapshots. A DAS28 calculated during a brief good spell between flares understates the disease, and a SLEDAI captured at the peak of a self-limiting viral illness can overstate it. Scores should be interpreted as part of a longitudinal record, corroborated by examination and investigations, and never used alone to start, stop or escalate immunosuppressive therapy. Treatment decisions in rheumatology remain clinical decisions informed by scores, not dictated by them.

How to use this library

Choose the calculator that matches the diagnosis: DAS28 for rheumatoid arthritis, SLEDAI for lupus. Enter the components as measured on the day, ideally with the joint counts from a proper examination and laboratory results no older than the current clinical picture. Read the resulting band or total alongside the trend from previous visits, because the direction of travel carries as much meaning as the number itself, and record the score in the notes so the next clinician inherits the trajectory, not just a single point.

Related specialities

• Pain Management
• Nephrology
• Hematology-Oncology
• Neurology

Frequently asked questions